Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its Q3 2025 earnings release for November 6, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day, featuring a corporate update and Q&A session. Investors can join via webcast or teleconference using the dial-in numbers 800-715-9871 (US) or 646-307-1963 (international) with access code 9073428. The webcast will be available on the company's investor relations website for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO), un'azienda di medicina rigenerativa specializzata nei mercati Advanced Wound Care e Chirurgia e Medicina dello Sport, ha fissato la data di pubblicazione dei suoi risultati del terzo trimestre 2025 al 6 novembre 2025, dopo la chiusura del mercato.
La direzione terrà una conference call alle 17:00 ora orientale nello stesso giorno, con un aggiornamento aziendale e una sessione di domande e risposte. Gli investitori possono partecipare tramite webcast o teleconferenza ai numeri 800-715-9871 (US) o 646-307-1963 (internazionale) con il codice di accesso 9073428. Il webcast sarà disponibile sul sito delle relazioni con gli investitori dell'azienda per circa un anno.
Organogenesis Holdings (Nasdaq: ORGO), una empresa de medicina regenerativa especializada en Advanced Wound Care y en los mercados de Cirugía y Medicina Deportiva, ha programado la publicación de resultados del tercer trimestre de 2025 para el 6 de noviembre de 2025, después del cierre del mercado.
La dirección ofrecerá una conference call a las 17:00 hora del Este el mismo día, con una actualización corporativa y una sesión de preguntas y respuestas. Los inversores pueden unirse vía webcast o teleconferencia utilizando los números de marcación 800-715-9871 (EE. UU.) o 646-307-1963 (internacional) con el código de acceso 9073428. El webcast estará disponible en el sitio de relaciones con inversionistas de la empresa durante aproximadamente un año.
Organogenesis Holdings (Nasdaq: ORGO)는 재생의학 기업으로서 고급 상처 관리(Advanced Wound Care) 및 외과·스포츠 의학 분야에 주력하고 있으며, 2025년 11월 6일 마감 이후에 2025년 3분기 실적 발표를 예정했습니다.
경영진은 같은 날 미 동부 표준시 17:00에 기업 업데이트 및 Q&A 세션을 포함한 컨퍼런스콜을 개최합니다. 투자자들은 다자간 웹캐스트 또는 전화회의를 통해 미국 800-715-9871 또는 국제 646-307-1963으로 접속하고 접속 코드 9073428을 사용하면 됩니다. 웹캐스트는 회사의 투자자 관계 웹사이트에서 약 1년간 이용할 수 있습니다.
Organogenesis Holdings (Nasdaq: ORGO), entreprise de médecine régénérative spécialisée dans les soins avancés des plaies et les marchés de la chirurgie et de la médecine du sport, a prévu la publication des résultats du T3 2025 pour le 6 novembre 2025, après la clôture du marché.
La direction animera une conférence téléphonique le même jour à 17 h 00, heure de l'Est, comportant une mise à jour d'entreprise et une séance de questions-réponses. Les investisseurs peuvent se joindre via webcast ou téléconférence en composant les numéros 800-715-9871 (États-Unis) ou 646-307-1963 (international) avec le code d'accès 9073428. Le webcast sera disponible sur le site des relations investisseurs de l'entreprise pendant environ un an.
Organogenesis Holdings (Nasdaq: ORGO), ein Unternehmen der regenerativen Medizin, spezialisiert auf fortschrittliche Wundversorgung sowie Chirurgie und Sportmedizin, hat die Veröffentlichung der Q3-2025-Ergebnisse auf den 6. November 2025 nach Börsenschluss terminiert.
Das Management wird am gleichen Tag eine Konferenzschaltung um 17:00 Uhr US-Ostzeit abhalten, mit einem Unternehmensupdate und einer Fragerunde. Investoren können sich per Webcast oder Telefonkonferenz verbinden, über die Rufnummern 800-715-9871 (US) oder 646-307-1963 (international) und dem Zugangscode 9073428. Der Webcast wird auf der Investor-Relations-Website des Unternehmens ca. ein Jahr lang verfügbar sein.
Organogenesis Holdings (Nasdaq: ORGO)، شركة متخصصة في الطب التجديدي وتخدم أسواق رعاية الجروح المتقدمة والجراحة والطب الرياضي، قد حددت إصدار نتائج الربع الثالث لعام 2025 في 6 نوفمبر 2025 بعد إغلاق السوق.
ستستضيف الإدارة مكالمة مؤتمر في الساعة 5:00 مساءً بتوقيت شرق الولايات المتحدة في اليوم نفسه، مع تحديث مؤسسي وجلسة أسئلة وأجوبة. يمكن للمستثمرين الانضمام عبر الويب أو الهاتف باستخدام أرقام الاتصال 800-715-9871 (الولايات المتحدة) أو 646-307-1963 (الدولي) مع رمز الدخول 9073428. سيكون البث عبر الويب متاحاً على موقع علاقات المستثمرين الخاص بالشركة لمدة حوالي عام.
Organogenesis Holdings (纳斯达克：ORGO)，一家专注于再生医学的公司，覆盖先进创面护理及外科和运动医学市场，已将其<都是ৃত Q3 2025 的业绩披露日定为< b>2025 年 11 月 6 日，收盘后。
管理层将在同一天举行一场 美国东部时间 17:00 的电话会议，提供公司更新和问答环节。投资者可通过 webcast 或电话会议加入，拨打美国电话 800-715-9871，国际号码 646-307-1963，访问码为 9073428。该网页广播将在公司投资者关系网站上提供约一年时间。
- None.
- None.
CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th.
Management will host a conference call at 5:00 p.m. Eastern Time on November 6th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the teleconference by dialing 800-715-9871 (646-307-1963 for international callers) and providing access code: 9073428. The live webcast can also be accessed via the company’s website at investors.organogenesis.com. The webcast will be archived on the company website for approximately one year.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.
Investor Inquiries: ICR Healthcare Mike Piccinino, CFA OrganoIR@icrinc.com Press and Media Inquiries: Organogenesis communications@organo.com
FAQ
When will Organogenesis (ORGO) report Q3 2025 earnings?
How can investors access the Organogenesis Q3 2025 earnings call?
Where can I find the replay of Organogenesis Q3 2025 earnings webcast?
What time is the Organogenesis (ORGO) Q3 2025 earnings call?
